Phase 2 Peripheral Neuropathy Trial, Recruiting NCT06318260 Sponsor: Steen Hvitfeldt Poulsen Condition: Peripheral Neuropathy
Back to Peripheral Neuropathy

Phase 2 Peripheral Neuropathy Trial, Recruiting

NCT06318260
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with wild-type transthyretin amyloid cardiomyopathy (a heart condition caused by protein build-up), confirmed through genetic testing, a bone scan, and/or a heart tissue biopsy.
  • People who are currently taking water pills (loop diuretics) to manage fluid build-up.
  • People whose heart failure symptoms fall into a moderate-to-severe range, as classified by a standard medical scale (New York Heart Association class II–IV).
  • People aged 65 years or older.
  • People whose heart is not pumping blood as efficiently as normal, based on measurements taken during a heart ultrasound (confirm with trial site for specific thresholds).
  • People who have given their full agreement to take part, both verbally and in writing.

Who may not be able to join:

  • People with moderate to severe narrowing of the aortic valve (mild valve changes alone would not necessarily prevent participation).
  • People with other significant heart valve problems.
  • People with serious blockages in the heart's arteries, such as blockage of the main left artery, blockage in three major arteries, or a heart attack within the past four weeks.
  • People who cannot safely receive the medication dobutamine — for example, due to a known allergy to dobutamine or sulfites, a type of adrenal gland tumour (phaeochromocytoma), or a serious irregular heart rhythm called ventricular tachycardia.
  • People with very advanced kidney disease, where the kidneys are functioning at a very low level.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 22 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 0045 91 65 18 48

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Steen Hvitfeldt Poulsen
Registry
ClinicalTrials.gov
Start date
8 April 2024
Est. completion
1 July 2026

Where this trial is recruiting

🇩🇰 Denmark

Primary endpoints

Cardiac output (CO)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov